Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 15, 2019 - Issue
Submit an article Journal homepage
183
Views
18
CrossRef citations to date
0
Altmetric
Review

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Kristen Ward1 Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA
&
Leslie Citrome2 Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA, [email protected]Correspondence[email protected]
Pages 247-257 | Published online: 15 Jan 2019

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mizue Ichinose, Itaru Miura, Sho Horikoshi, Shinnosuke Yamamoto, Keiko Kanno-Nozaki, Kenya Watanabe & Hirooki Yabe. (2021) Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder. Neuropsychiatric Disease and Treatment 17, pages 1047-1053.
Read now

Articles from other publishers (17)

John Cookson & Jonathan Pimm. (2021) Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances 29:2, pages 145-150.
Crossref
Nora Angélica Martínez-Vélez, Raul Ivan Escamilla Orozco, Yvonne Flores Medina, Ricardo A Saracco-Alvarez, Mauricio Rosel Vales, Ismael Aguilar-Salas & Graciela Yazmín Sánchez-Hernández. (2023) Aripiprazole versus brexpiprazole for people with schizophrenia. Cochrane Database of Systematic Reviews 2023:2.
Crossref
Mujeeb U. Shad. (2023) Seventy Years of Antipsychotic Development: A Critical Review. Biomedicines 11:1, pages 130.
Crossref
I. V. Oleichik, T. I. Shishkovskaya, P. A. Baranov & I. Yu. Nikiforova. (2022) Features of Clinical Use of Brexpiprazole, the New Atypical Antipsychotic of the Third Generation: Experience and Perspectives. Psikhiatriya 20:3, pages 134-142.
Crossref
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, Megan Elizabeth Good & Rif S. El-Mallakh. (2021) New Antipsychotic Medications in the Last Decade. Current Psychiatry Reports 23:12.
Crossref
Matej Ľupták, Zdeněk Fišar & Jana Hroudová. (2021) Effect of Novel Antipsychotics on Energy Metabolism — In Vitro Study in Pig Brain Mitochondria. Molecular Neurobiology 58:11, pages 5548-5563.
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels 337 371 .
Hiroshi Kimura, Nobuhisa Kanahara & Masaomi Iyo. (2021) Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behavioural Brain Research 403, pages 113126.
Crossref
Stephen M. Stahl. 2021. Prescriber's Guide. Prescriber's Guide 103 110 .
Stephen M. Stahl. 2021. Prescriber's Guide. Prescriber's Guide.
Samskruthi Madireddy & Sahithi Madireddy. (2020) Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia. Brain Sciences 10:10, pages 742.
Crossref
Lauren Stummer, Marija Markovic & Megan Maroney. (2020) Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer’s disease. Neurodegenerative Disease Management 10:4, pages 205-217.
Crossref
Alexandre González-Rodríguez, Javier Labad & Mary V. Seeman. (2020) Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. Progress in Neuro-Psychopharmacology and Biological Psychiatry 101, pages 109941.
Crossref
Ayman Antoun Reyad, Eriny Girgis & Raafat Mishriky. (2020) Efficacy and safety of brexpiprazole in acute management of psychiatric disorders. International Clinical Psychopharmacology 35:3, pages 119-128.
Crossref
Nicholas Keks, Judith Hope, Darren Schwartz, Harold McLennan, David Copolov & Graham Meadows. (2020) Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs 34:5, pages 473-507.
Crossref
Filippo Caraci, Mario Santagati, Giuseppe Caruso, Dario Cannavò, Gian Marco Leggio, Salvatore Salomone & Filippo Drago. (2020) New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin. F1000Research 9, pages 686.
Crossref
Anna Morozova, Yana Zorkina, Konstantin Pavlov, Olga Pavlova, Zinaida Storozheva, Eugene Zubkov, Natalia Zakharova, Olga Karpenko, Alexander Reznik, Vladimir Chekhonin & Georgiy Kostyuk. (2019) Association of rs4680 COMT, rs6280 DRD3, and rs7322347 5HT2A With Clinical Features of Youth-Onset Schizophrenia. Frontiers in Psychiatry 10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.